Monday, August 06, 2018 3:52:33 PM
During the month of July 2018, the Company continued optimizing and improving the components of the FAIMS Point of Care (“POC”) prototype device, namely the ionization source and FAIMS waveform generator. The R&D Team plans to further develop the device, as well as implement findings from ongoing research conducted on biomarkers found in the breath that are associated with diseases. The Company also continues to evaluate the potential commercial impact of an assortment of biomarkers tested so far to determine the most effective strategy going forward.
My lottery tickets: Blozf, Glh, Splif, Gbb
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM